The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Alpha FX restarts relationship; Atalaya resources up

Tue, 05th Apr 2022 21:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Alpha FX Group PLC - London-based foreign exchange risk management and international payments - Restarts trading relationship with unnamed "key" Norwegian client. Entered settlement agreement with client in March 2020 at onset of Covid pandemic, where the client was required to make weekly repayments until June 2022 in respect of their obligations for unpaid margins. "Since this date, the client's financial standing has continued to strengthen, and they have consistently met all 104 of their weekly repayment obligations on time. As a result, the gross balance outstanding as at April 1, 2022 has been reduced to GBP2.9 million," company says. Notes it will allow clients to pay outstanding amount over rest of 2022, extending deadline past June 2022.

----------

Marlowe PLC - London-based company focused on business safety and regulatory compliance - Says at Capital Markets Day its trading has been "strong" and expects to meet 2024 strategic and financial targets "materially ahead of schedule". Company says the "significant development" in building its compliance platform - which now encompasses intelligence, consultancy, software and assurance - the reason behind strong trading.

----------

Aferian PLC - Leeds-based video streaming - Acquires 100% share capital of Exabre Ltd, trading as The Filter, a UK-headquartered AI-powered video recommendation service. Initial consideration of deal will GBP1.5 million in cash, with up to GBP2.5 million subject to achieving certain annual recurring revenue growth at increments of additional ARR of GBP500,000. Company says: "The Filter's technology will significantly accelerate the roadmap of 24i's video streaming platform by adding enhanced analytics, recommendations and personalisation to its existing data analytics services. 24i will also market The Filter's managed service solution to its existing OTT and Pay TV customers and prospects as a standalone service."

----------

Glantus Holdings PLC - Dublin-based accounts payable automation and analytics - Agrees new partnership with TealBook, a supplier data firm that powers e-procurement technology. "This partnership will enable customers of both parties to access robust supplier information and insights and stronger AP intelligence," company explains. Adds: "The referral party vendor and supplier information through TealBook's comprehensive supplier intelligence capabilities will enable TealBook customers to utilize the Glantus data analytics solution to understand opportunities for efficiency and risk mitigation within their AP operations and payments."

----------

Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Agrees collaboration with the Garvan Institute of Medical Research, an Australian medical research institute, which expands on company's preclinical work already underway. "The collaboration aims to better understand treatments that could lead to increased patient survival in currently very poorly treated highly fibrotic cancers, such as pancreatic cancer," company says. Adds: "Through this collaboration, Redx and the Garvan will develop an enhanced understanding of cancer-associated fibrosis through detailed scientific studies utilising patient-derived tumour tissue grown in mice, which is thereby able to mimic human disease as closely as possible."

----------

e-Therapeutics PLC - Oxford, England-based computational drug discovery - Enters research collaboration agreement with iTeos Therapeutics Inc, a clinical-stage biopharmaceutical company focused on discovery and development of a new generation of immuno-oncology therapeutics. "The collaboration will focus on the discovery of novel therapeutic approaches and targets in immuno-oncology. e-therapeutics will remain free to explore additional collaborations in the space," company explains. e-therapeutics will receive upfront and near-term cash payments material to the revenue of the company.

----------

Atalaya Mining PLC - copper miner in Spain - Sees "significant" increase in mineral resources at Proyecto Masa Valverde. PMV is located in the Iberian Pyrite Belt of southern Spain. PMV consists of two deposits, Masa Valverde and Majadales. Sees increase in tonnage and contained copper, silver and gold from prior estimate of 42%, 33%, 26% and 34%, respectively. Masa Valverde initial indicated mineral resource now 16.9 million tonnes at 0.66% copper, 1.55% zinc, 0.65% lead, and 27 grammes per tonne silver and 0.55 grammes per tonne gold. Chief Executive Alberto Lavandeira says: "We remain excited about the continued exploration potential at PMV, given the many anomalies our exploration team has identified. We hope to make further discoveries, building on our success in discovering the Majadales deposit, which is shallower and higher grade than Masa Valverde and thus may play a key role in optimising future development scenarios."

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
24 Feb 2016 09:44

Redx Pharma Makes Progress On Gonorrhoea Treatment And Other Drugs

Read more
20 Jan 2016 10:00

Redx Pharma Continues Pipeline Progressing In Maiden Results

Read more
13 Jan 2016 16:00

Earnings, Trading Statements Calendar - Week Ahead

Read more
4 Jan 2016 08:35

New Redx director brings scientific, commercial expertise

(ShareCast News) - Redx announced the appointment of a non-executive director on Monday, with Dr Bernhard Kirschbaum joining the firm's board immediately. The AIM-listed self-described drug discovery and development company said Dr Kirschbaum was bringing with him more than 25 years experience in ph

Read more
3 Dec 2015 07:54

Redx Pharma Identifies New Cancer Drug Development Candidate

Read more
6 Nov 2015 09:42

DIRECTOR DEALINGS: Redx Pharma Chairman, Non-Executives Buy Shares

Read more
1 Oct 2015 07:36

Redx Pharma Says It Made "Good Progress" In Second Half

Read more
3 Sep 2015 08:00

Redx Pharma And Horizon Discovery Collaborating On Cancer Research

Read more
22 Jun 2015 14:17

Redx Pharma enjoys good progress during first-half

Two months after its admission to AIM, Redx Pharma said its first-half results were in line with expectations thanks to progress on potential MRSA drugs. Losses before tax rose 60.5% to £3.26m due to a decrease in grant funding and operating expenses increased 5% to £5.48m. The drug discovery and d

Read more
22 Jun 2015 08:35

Redx Pharma Positive For Full Year, Loss Widens In Maiden Interims

Read more
2 Jun 2015 11:13

Redx Pharma cheers with progress on potential MRSA drug

Redx shares jumped on the news it has reached the pre-clinical development stage with a new anti-infective compound designed to tackle MRSA, the bacteria that causes potentially lethal infections in humans. The pharmaceutical firm said the progress marked a "significant milestone" for its commercial

Read more
2 Jun 2015 07:00

Redx Pharma Progresses To Pre-Clinical Stage With MRSA Treatment

Read more
26 May 2015 07:43

Redx Pharma Identifies Second Drug Development Candidate

Read more
14 May 2015 09:41

Redx Pharma To Launch New Immunology Subsidiary

Read more
14 May 2015 08:55

Redx Pharma Says Third Paper On Antimicrobial Resistance Published

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.